BR112018067789A2 - análogos de nucleosídeos substituídos para uso como inibidores de prmt5 - Google Patents

análogos de nucleosídeos substituídos para uso como inibidores de prmt5

Info

Publication number
BR112018067789A2
BR112018067789A2 BR112018067789A BR112018067789A BR112018067789A2 BR 112018067789 A2 BR112018067789 A2 BR 112018067789A2 BR 112018067789 A BR112018067789 A BR 112018067789A BR 112018067789 A BR112018067789 A BR 112018067789A BR 112018067789 A2 BR112018067789 A2 BR 112018067789A2
Authority
BR
Brazil
Prior art keywords
nucleoside analogs
substituted nucleoside
prmt5 inhibitors
compounds
present
Prior art date
Application number
BR112018067789A
Other languages
English (en)
Other versions
BR112018067789B1 (pt
Inventor
Boeckx An
Christopher Shook Brian
Jean-Claude Berthelot Didier
BREHMER Dirk
Charles LAWSON Edward
Stanislas Marcella Diels Gaston
Wilhelmus John F Thuring Johannes
Meerpoel Lieven
BEKE Lijs
Viellevoye Marcel
Cornelis Bernardus Catharina Paradé Marcus
Arnodus Hendrika Joseph Gilissen Ronaldus
Wu Tongfei
Pande Vineet
Sun Weimei
Bert Griet Schepens Wim
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority claimed from PCT/EP2017/054324 external-priority patent/WO2017153186A1/en
Publication of BR112018067789A2 publication Critical patent/BR112018067789A2/pt
Publication of BR112018067789B1 publication Critical patent/BR112018067789B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

a presente invenção refere-se a novos análogos de nucleosídeos substituídos de fórmula (i) em que as variáveis têm o significado definido nas reivindicações. os compostos de acordo com a presente invenção são úteis como inibidores de prmt5. a invenção refere-se adicionalmente às composições farmacêuticas compreendendo os referidos compostos como ingrediente ativo bem como com o uso dos referidos compostos como medicamento.
BR112018067789-2A 2016-03-10 2017-02-24 Análogos de nucleosídeos substituídos, composição farmacêutica que os compreende e uso BR112018067789B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662306222P 2016-03-10 2016-03-10
US62/306,222 2016-03-10
EP16162731.0 2016-03-30
EP16162731 2016-03-30
PCT/EP2017/054324 WO2017153186A1 (en) 2016-03-10 2017-02-24 Substituted nucleoside analogues for use as prmt5 inhibitors

Publications (2)

Publication Number Publication Date
BR112018067789A2 true BR112018067789A2 (pt) 2019-04-30
BR112018067789B1 BR112018067789B1 (pt) 2023-12-12

Family

ID=65443152

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018067789-2A BR112018067789B1 (pt) 2016-03-10 2017-02-24 Análogos de nucleosídeos substituídos, composição farmacêutica que os compreende e uso

Country Status (11)

Country Link
US (1) US10898504B2 (pt)
JP (1) JP6909799B2 (pt)
BR (1) BR112018067789B1 (pt)
EA (1) EA201892031A1 (pt)
ES (1) ES2891320T3 (pt)
MA (1) MA43671A (pt)
MX (1) MX2018010923A (pt)
PH (1) PH12018501895A1 (pt)
TN (1) TN2018000310A1 (pt)
UA (1) UA123637C2 (pt)
ZA (1) ZA201806016B (pt)

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224438A (en) 1970-07-14 1980-09-23 Boehringer Mannheim Gmbh Adenosine-5'-carboxylic acid amides
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
AU2002351077A1 (en) 2001-11-05 2003-05-19 Exiqon A/S Oligonucleotides modified with novel alpha-l-rna analogues
US7034147B2 (en) * 2001-11-29 2006-04-25 Irm Llc Nucleoside analog libraries
US7144871B2 (en) 2002-02-19 2006-12-05 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US20040043959A1 (en) * 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
US20080033172A1 (en) 2003-12-19 2008-02-07 Koronis Pharmaceuticals, Incorporated Mutagenic Heterocycles
EP1844062A2 (en) 2005-01-21 2007-10-17 Methylgene, Inc. Inhibitors of dna methyltransferase
US20080132525A1 (en) 2006-12-04 2008-06-05 Methylgene Inc. Inhibitors of DNA Methyltransferase
WO2010039548A2 (en) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
AU2010330823A1 (en) 2009-12-18 2012-07-05 Joslin Diabetes Center, Inc. Beta-cell replication promoting compounds and methods of their use
AU2011341441A1 (en) 2010-12-03 2013-06-20 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
RU2013130253A (ru) 2010-12-03 2015-01-10 Эпизайм, Инк. 7-деазапуриновые регуляторы метилтрансферазы гистонов и способы их применения
MX2013006951A (es) 2010-12-16 2013-10-03 Abbvie Inc Compuestos antivirales.
EP2694524B1 (en) 2011-04-04 2016-05-18 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services 2'-o-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
US20140100184A1 (en) 2012-08-31 2014-04-10 Baylor College Of Medicine Selective inhibitors of histone methyltransferase dot1l
EP2935243B1 (en) 2012-12-21 2018-03-14 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
HUE040323T2 (hu) 2012-12-21 2019-02-28 Epizyme Inc PRMT5-inhibitorok és alkalmazásaik
WO2014100695A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
JP6510539B2 (ja) 2014-01-09 2019-05-08 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ， ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デヴィッド グラッドストーン 置換ベンゾオキサジン及び関連化合物
US20170198006A1 (en) 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
BR112017017396A2 (pt) 2015-02-24 2018-04-03 Pfizer derivados substituídos de nucleosídeos substituídos úteis como agentes anticancerígenos
TW202321249A (zh) * 2015-08-26 2023-06-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６－６雙環芳香環取代之核苷類似物
US10685416B2 (en) 2015-12-10 2020-06-16 Uber Technologies, Inc. Suggested pickup location for ride services
WO2017153186A1 (en) 2016-03-10 2017-09-14 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as prmt5 inhibitors
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
UA127679C2 (uk) 2017-02-27 2023-11-29 Янссен Фармацевтика Нв Спосіб ідентифікації пацієнта, що характеризується наявністю сприйнятливості до лікування недрібноклітинного раку легені інгібітором prmt5

Also Published As

Publication number Publication date
ES2891320T3 (es) 2022-01-27
UA123637C2 (uk) 2021-05-05
US10898504B2 (en) 2021-01-26
TN2018000310A1 (en) 2020-01-16
BR112018067789B1 (pt) 2023-12-12
ZA201806016B (en) 2022-04-28
JP6909799B2 (ja) 2021-07-28
US20200289539A1 (en) 2020-09-17
MX2018010923A (es) 2019-02-13
MA43671A (fr) 2018-11-28
EA201892031A1 (ru) 2019-02-28
JP2019507778A (ja) 2019-03-22
PH12018501895A1 (en) 2019-05-20

Similar Documents

Publication Publication Date Title
BR112018003595A2 (pt) análogos de nucleosídeos substituídos no anel aromático 6-6 bicíclico para uso como inibidores de prmt5
BR112018076169A2 (pt) derivados azabenzimidazol como inibidores de pi3k beta
CO2017006214A2 (es) Derivados de quinazolina utilizados para tratar el vih
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
BR112017002053A2 (pt) composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto
BR112019006414A2 (pt) análogos de carbanucleosídeos de sistema de anel monocíclico e bicíclico substituídos para uso como inibidores de prmt5
BR112018005932A2 (pt) inibidores de isoindolinona da interação de mdm2-p53 que têm atividade anticâncer
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
UY35300A (es) Formulación de combinación de dos compuestos antivirales
BR112013020996A8 (pt) derivados aminobutíricos substituídos como inibidores de neprilisina
BR112017002214A2 (pt) composto de fórmula (i), composição farmacêutica e usos de um composto
BR112017004741A2 (pt) compostos e composições como inibidores da raf quinase
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112019021867A2 (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil
BR112018007068A2 (pt) derivados de quinoxalina e piridopirazina como inibidores de pi3kbeta
BR112017018305A2 (pt) desacetoxitubulisina h e análogos da mesma
BR112018011525A2 (pt) inibidores da tirosina quinase de bruton e métodos de seu uso
BR112014018636A8 (pt) Derivados de benzil sulfonamida úteis como inibidores de mogat-2
BR112015024971A2 (pt) derivados de n-(2,3-di-hidro-1h-pirrolo[2,3-b]piridin-5-il)-4-quinazolinamina e n-(2,3-di-hidro-1h-indol-5-il)-4-quinazolinamina como inibidores de perk
BR112017004991A2 (pt) compostos antimicrobianos de imidazólio
UY37191A (es) Derivados de dibenzofurano para uso como inhibidores de bromodominio
BR112017012930A2 (pt) derivados de imidazopiridazina como inibidores de pi3kbeta.
BR112018076734A2 (pt) compostos heterocíclicos anti-infecciosos e usos dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/02/2017, OBSERVADAS AS CONDICOES LEGAIS